JOURNAL ARTICLE

Amgen Discloses FDA Paused Study of Early-Stage Obesity Drug.

  • Published In: Bloomberg.com, 2025. P. N.PAG 1 of 3

  • Database: Business Source Ultimate 2 of 3

  • Authored By: Muller, Madison 3 of 3

Abstract

Amgen Inc. disclosed that the US FDA paused the study of an early-stage obesity drug, AMG-513, without specifying the reason or timeline for the hold. The company is working with the FDA to address the issue and continue development. Investors are closely watching Amgen's progress in the obesity market, as analysts predict significant growth in the sector, with the potential market size reaching $130 billion by 2030. Despite facing patent expirations and competition in other drug categories, Amgen anticipates strong revenues in 2025, driven by growth in cholesterol and cancer drugs. [Extracted from the article]

Additional Information

  • Source:Bloomberg.com. 2025/02, pN.PAG
  • Document Type:Article
  • Subject Area:Politics and Government
  • Publication Date:2025
  • Accession Number:182774303
  • Copyright Statement:Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.